Drugs / IMS001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04956744 | Aug 2021 → Dec 2027 expected | multiple sclerosis | ImStem Biotechnology | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMS001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04956744 ↗ |
| Modality | Cell therapy | “human embryonic cell derived (hESC) mesenchymal stem cell (MSC)” NCT04956744 ↗ |
| Route | Intravenous | “intravenous (IV) IMS001” NCT04956744 ↗ |